Compounds > n-(2-hydroxyethyl)retinamide
Page last updated: 2024-08-02 00:09:13

n-(2-hydroxyethyl)retinamide

Description

N-(2-hydroxyethyl)retinamide: RN given refers to cpd without isomeric designation [MeSH]

Cross-References

ID SourceID
PubMed CID6437840
CHEMBL ID60405
SCHEMBL ID2467990
MeSH IDM0077843

Synonyms (20)

Synonym
retinoic acid 2-hydroxyethylamide
retinamide, n-(2-hydroxyethyl)-
brn 2161307
2-hydroxyethyl retinamide
n-2-hydroxyethyl retinamide
hydroxyethyl retinamide
ro 8-4969
n-(2-hydroxyethyl)retinamide
ccris 4284
CHEMBL60405 ,
(2e,4e,6e,8e)-n-(2-hydroxyethyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
33631-47-9
bdbm50347597
SCHEMBL2467990
ro-8-4969
DTXSID801309774
hydroxyethyl)retinamide, all-trans-4-n-(2-
ZBJ8HC23XW
(2e,4e,6e,8e)-n-(2-hydroxyethyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide
2-hydroxyethylretinamide

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Retinol-binding protein 4Homo sapiens (human)EC500.1450AID606066
Retinol-binding protein 4Homo sapiens (human)Kd0.2140AID606062

Bioassays (6)

Assay IDTitleYearJournalArticle
AID606163Binding affinity to immobilized His-tagged recombinant human sRBP assessed as inhibition of sRBP and detergent treated HEK293 membrane interaction at 100 uM after 1 hr by surface plasmon resonance assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID606064Binding affinity to His-tagged recombinant human sRBP expressed in Escherichia coli BL21(DE3) assessed as disruption of sRBP-TTR protein interaction after 1 hr by SDS-PAGE and silver staining method2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID606161Antagonist activity at His-tagged recombinant human sRBP expressed in Escherichia coli BL21(DE3) assessed as disruption of ROH-sRBP-TTR protein interaction after 2 hr by TR-FRET assay relative to control2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID606062Binding affinity to His-tagged recombinant human sRBP expressed in Escherichia coli BL21(DE3) assessed as apparent dissociation constant after 5 mins by fluorescence spectrophotometric analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID84861Reversal of keratinization in vitamin A deficient hamster trachea culture1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
ISSN: 0022-2623		N-(Retinoyl)amino acids. Synthesis and chemopreventive activity in vitro.
AID606066Antagonist activity at His-tagged recombinant human sRBP expressed in Escherichia coli BL21(DE3) assessed as disruption of ROH-sRBP-TTR protein interaction after 2 hr by TR-FRET assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
ISSN: 1520-4804		Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (90.91)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
tretinoin
1
retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule		1988198836.0low010000
retinol
1
retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite		2011201113.0low000010
isotretinoin
1
retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent		1988198836.0low010000
vitamin a acid ethylamide
1
1988198836.0low010000
fenretinide
2
monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant		1988201124.5low010010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
thiazoles
1
1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		1981198143.0low010000
methylnitrosourea
1
N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent		1981198143.0low010000
butylhydroxybutylnitrosamine
2
nitrosamine;
primary alcohol		carcinogenic agent1981198541.0low020000
fanft
1
1981198143.0low010000
nitrosobis(2-oxopropyl)amine
2
ketone;
nitrosamine		carcinogenic agent1981198342.0low020000
tretinoin
9
retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule		1980198541.9high090000
azaserine
1
carboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid		antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite		1984198440.0low010000
isotretinoin
3
retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent		1980198342.7low030000
vitamin a acid ethylamide
7
1980198342.6high070000
fenretinide
2
monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant		1981198342.0low020000
retinylidene dimedone
1
1984198440.0medium010000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Amyloidosis0
1
1981198143.0low010000
Anemia0
1
1983198341.0low010000
Atrophy0
1
1980198044.0low010000
Benign Neoplasms0
1
1983198341.0low010000
Bladder Cancer0
3
1981198541.7low030000
Body Weight0
2
1981198342.0low020000
Cancer of Pancreas0
3
1981198441.3low030000
Carcinoma0
2
1981198143.0low020000
Carcinoma, Anaplastic0
2
1981198143.0low020000
Carcinoma, Transitional Cell0
1
1981198143.0low010000
Condition, Preneoplastic0
1
1981198143.0low010000
Experimental Neoplasms0
4
1981198143.0medium040000
Metaplasia0
1
1988198836.0low010000
Neoplasms0
1
1983198341.0low010000
Pancreatic Neoplasms0
3
1981198441.3low030000
Precancerous Conditions0
1
1981198143.0low010000
Tracheal Neoplasms0
1
1981198143.0low010000
Urinary Bladder Neoplasms0
3
1981198541.7low030000

Safety/Toxicity (1)

ArticleYear
Subacute toxicity of all-trans- and 13-cis-isomers of N-ethyl retinamide, N-2-hydroxyethyl retinamide, and N-4-hydroxyphenyl retinamide.
Toxicology and applied pharmacology, , Sep-15, Volume: 70, Issue:2		1983

Dosage (2)

ArticleYear
Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 10, Issue:4
The pharmacokinetics of all-trans-retinoic acid and N-(2-hydroxyethyl)retinamide in mice as determined with a sensitive and convenient procedure. Solid-phase extraction and reverse-phase high performance liquid chromatography.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 15, Issue:2